Published in: Journal of Law, Medicine, and Ethics
Description: Mark Barnes, Faculty Co-Director of the MRCT Center and partner at Ropes & Gray, with co-authors, published International Ethical Principles for Banking and Secondary Research Use of Human Biospecimens and Associated Data: The Seattle Principles in the Journal of Law, Medicine & Ethics. International biospecimen sharing is essential to advancing science and developing therapies that benefit all populations — yet the field lacks a harmonized ethical and regulatory framework across jurisdictions. Drawing on extensive stakeholder engagement through forums including ISBER, PRIM&R, and the UN General Assembly Science Summit, the authors propose eleven foundational principles covering transparency, consent, privacy, community welfare, governance, and responsible stewardship of biospecimen resources, with the goal of establishing common ethical ground for the global research community.
Published in: Journal of Law, Medicine, and Ethics
Description: Benjamin Silverman of Mass General Brigham, Barbara Bierer, and MRCT Center colleague Willyanne DeCormier Plosky, with co-authors, published Supported Decision-Making for Clinical Research Participants with Mental Illness in the Journal of Law, Medicine, and Ethics. Because mental illness can be dynamic and variable in nature, decision-making capacity presents nuanced challenges for research participation. The authors examine supported decision-making — a strategy that enables individuals to select trusted others to help them understand and communicate decisions — with particular attention to the implications for people with intermittent or episodic mental illness.
Published in: Therapeutic Innovation & Regulatory Science
Description: In “Parents’ Perspectives on Access to Pediatric Rare Disease Cross-Border Clinical Trials in Europe: Experiences of Language Inclusion and Preferences,” published in Therapeutic Innovation & Regulatory Science, Barbara Bierer and co-authors analyze findings from a survey of 1,436 parents across 34 European countries on their experiences with and preferences for cross-border clinical trial participation. Among families who reported being excluded from a trial abroad, 34.7% cited language barriers or country of residence as the reason. The authors conclude that language accommodation is feasible and should be incorporated into trial design, and that language should be used as an eligibility criterion only when scientifically justified.
Description: In “Genetic Therapies for Rare Diseases: Developing Ethical Regulatory Policies,” a commentary published in the Hastings Bioethics Forum, Carolyn Riley Chapman, former lead of the MRCT Center’s Cell and Gene Therapies project, and co-author Nirvan Bhatia argue that the U.S. should adopt a differentiated approval system for gene-based therapies for rare diseases, conferring different tiers of regulatory approval based on different levels of evidence. The authors contend that this approach would improve patient access to innovative therapies while increasing transparency about evidentiary standards and providing stronger incentives for timely post-marketing studies. The MRCT Center’s Toolkit for Supporting the Design and Conduct of Long-Term Follow-Up Studies for Gene Therapies, released in January, offers practical guidance on related challenges in gene therapy research.
What does it take to deploy digital twins and synthetic data in clinical evidence generation — and what do regulators expect when you do?
In this third webinar in the MRCT Center’s Digital Twins and Synthetic Data series, a multidisciplinary panel examines the real-world application of these technologies across the clinical trial lifecycle. The discussion covers evidence quality and validation, regulatory benchmarks, model transparency, and the evolving landscape of FDA and EMA expectations. Panelists draw on experience spanning machine learning, FDA policy development, and drug development leadership to offer practical, grounded perspectives on what adoption looks like today — and where the field is headed.
Topics include:
Defining digital twins and synthetic data: key distinctions and appropriate uses
Reducing control arms and enhancing statistical power in randomized and single-arm trials
Applications across rare disease, oncology, and common conditions
Machine learning vs. traditional statistical approaches: complementary, not competing
Regulatory acceptance: FDA draft guidance, EMA qualification of PROCOVA, and engagement strategies
Model evaluation benchmarks and performance validation across development phases
Cultural and organizational barriers to adoption — and how to address them
Panelists: Daniele Bertolini, Principal Machine Learning Scientist, Unlearn.AI | Tala Fakhouri, VP Consulting AI & Digital Policy and Real World Evidence, Parexel | Karen Smith, Board Director, Context Therapeutics, Skye Bioscience, and Sangamo Therapeutics
Moderator: Barbara Bierer, Faculty Director, MRCT Center
Published in:Journal of Clinical and Translational Science
Abstract: Barbara Bierer and MRCT Center colleagues Walker Morrell, Ava Glazier, and Deborah Zarin, together with Luke Gelinas of Advarra and Tony Tse of the National Institutes of Health, published Characterization of Key Information Sections in Informed Consent Forms Posted on ClinicalTrials.gov in the Journal of Clinical and Translational Science. The 2018 revised Common Rule requires informed consent forms to open with a “concise and focused” key information (KI) section, but provides no guidance on content or format. Analyzing federally funded treatment trial ICFs posted on ClinicalTrials.gov, the authors found that three-quarters included an identifiable KI section averaging one page—yet readability showed little improvement over full ICFs, and a meaningful minority omitted core content such as the main reasons to join or not join a study. The authors call for consensus-based guidelines to help researchers and IRBs develop KI sections that are both compliant and genuinely useful to participants.
Gelinas L, Morrell W, Tse T, Glazier A, Zarin DA, Bierer BE. Characterization of key information sections in informed consent forms posted on ClinicalTrials.gov. Journal of Clinical and Translational Science. 2023;7(1):e185. doi:10.1017/cts.2023.605
Description: Barbara Bierer, Ava Glazier, and Willyanne DeCormier Plosky published “Disclosure of Pregnancy-Related Privacy Risks in Clinical Research Post-Dobbs” in NEJM Evidence. The review examines how routine clinical research practices — such as pregnancy testing, contraception requirements, and incidental pregnancy reporting — have created new privacy risks for participants, clinicians, and investigators following the 2022 Dobbs v. Jackson Women’s Health Organization decision and offers practical guidance for investigators and IRBs navigating this shifting legal landscape.
The MRCT Center held its Annual Symposium on October 22, 2025, hosting 100 people in Boston and 580 people virtually. Sessions focused on concrete implementation challenges in global clinical trials, including how to modernize trial operations, reduce inefficiencies, alleviate site and participant burden, reimagine informed consent as an enabling participant-centered process, and adopt the responsible use of AI. The MRCT Center Long-Term Follow-Up Toolkit was introduced.
John F. Crowley, President & CEO, Biotechnology Innovation Organization (BIO) A call for regulatory modernization, trial simplification, and cross-sector partnership to sustain innovation and expand equitable access to medicines worldwide.
Kevin Bugin (Amgen); Karen Hartman (Mayo Clinic); Bridgette René McCullough (ACIRAH Health); Ann Meeker-O’Connell (Novartis) Practical reforms to reduce protocol complexity and site burden, standardize systems, accelerate start-up, and expand patient access through adaptive and decentralized trial designs.
Sarah White, Executive Director, MRCT Center Repositioning the MRCT Center to remain nimble and opportunistic amid regulatory, technological, and operational uncertainty through focused work on access, innovative trial design, data use and protection, patient-centered approaches, responsive forums, global capacity building, and artificial intelligence.
Michael Cohen-Wolkowiez (Duke University); Megan Doerr (Sage Bionetworks); Cristin Freeman (Bristol Myers Squibb) Real-world applications of AI to enhance informed consent, focusing on participant-centered, scalable, and feasible innovation, while respecting ethical and regulatory expectations.
Willyanne DeCormier Plosky; Sarah White; Sylvia Baedorf Kassis; Lisa Koppelman; Barbara Bierer (MRCT Center) Implementation updates on Representation in Research, capacity building through the TRACE Project, workforce competency standards (JTF), pediatric research, and the European Health Data Space.
Save the date: The 2026 MRCT Center Annual Symposium will take place on Wednesday, October 21, 2026, in Boston. An agenda will be shared in the coming months.
Available now on Spotify, YouTube, Apple Podcasts, and all streaming platforms. Subscribe to the MRCT Center Podcast to see the full library of conversations.
